Pharmacological evidence of medicinal cannabis in oncology: a systematic review.

Brown, D; Watson, M; Schloss, J

Pharmacological evidence of medicinal cannabis in oncology: a systematic review.

Brown, D Watson, M Schloss, J

Permalink

Publisher:: Springer Science and Business Media LLC
Publication Type:: Journal Article
Citation:: Support Care Cancer, 2019, 27, (9), pp. 3195-3207
Issue Date:: 2019-09

Closed Access

	Filename	Description	Size
	s00520-019-04774-5.pdf	Published version	541.94 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Brown, D
dc.contributor.author	Watson, M
dc.contributor.author	Schloss, J https://orcid.org/0000-0003-1643-6215
dc.date.accessioned	2022-10-30T00:59:57Z
dc.date.available	2019-03-25
dc.date.available	2022-10-30T00:59:57Z
dc.date.issued	2019-09
dc.identifier.citation	Support Care Cancer, 2019, 27, (9), pp. 3195-3207
dc.identifier.issn	0941-4355
dc.identifier.issn	1433-7339
dc.identifier.uri	http://hdl.handle.net/10453/162886
dc.description.abstract	PURPOSE: This systematic literature review examines research into the use of medicinal cannabis in cancer management. The aim was to identify the gaps in knowledge on the dose, dosing schedule and absorption of the administration routes of medicinal cannabis use in oncology. METHODS: A comprehensive search of the literature was conducted across six databases to identify original data reporting the pharmacology of medicinal cannabis in oncology. RESULTS: Eighteen articles were selected for review. Of the selected articles, ten were identified as randomised control trials, two experimental studies, two retrospective cohort studies and four case studies. Four articles reported absorption data and one drug interaction study was identified. CONCLUSIONS: There is little evidence reported in the literature on the absorption of medicinal cannabis in cancer populations. Various reasons are explored for the lack of pharmacokinetic studies for medicinal cannabis in cancer populations, including the availability of assays to accurately assess cannabinoid levels, lack of clinical biomarkers and patient enrolment for pharmacokinetic studies.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	Support Care Cancer
dc.relation.isbasedon	10.1007/s00520-019-04774-5
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Analgesics
dc.subject.mesh	Antiemetics
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Cannabinoids
dc.subject.mesh	Cannabis
dc.subject.mesh	Cholinergic Antagonists
dc.subject.mesh	Drug Dosage Calculations
dc.subject.mesh	Humans
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Neoplasms
dc.subject.mesh	Plant Preparations
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Humans
dc.subject.mesh	Cannabis
dc.subject.mesh	Neoplasms
dc.subject.mesh	Cannabinoids
dc.subject.mesh	Cholinergic Antagonists
dc.subject.mesh	Analgesics
dc.subject.mesh	Antiemetics
dc.subject.mesh	Plant Preparations
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Drug Dosage Calculations
dc.subject.mesh	Medical Marijuana
dc.title	Pharmacological evidence of medicinal cannabis in oncology: a systematic review.
dc.type	Journal Article
utslib.citation.volume	27
utslib.location.activity	Germany
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2022-10-30T00:59:55Z
pubs.issue	9
pubs.publication-status	Published
pubs.volume	27
utslib.citation.issue	9

Abstract:

PURPOSE: This systematic literature review examines research into the use of medicinal cannabis in cancer management. The aim was to identify the gaps in knowledge on the dose, dosing schedule and absorption of the administration routes of medicinal cannabis use in oncology. METHODS: A comprehensive search of the literature was conducted across six databases to identify original data reporting the pharmacology of medicinal cannabis in oncology. RESULTS: Eighteen articles were selected for review. Of the selected articles, ten were identified as randomised control trials, two experimental studies, two retrospective cohort studies and four case studies. Four articles reported absorption data and one drug interaction study was identified. CONCLUSIONS: There is little evidence reported in the literature on the absorption of medicinal cannabis in cancer populations. Various reasons are explored for the lack of pharmacokinetic studies for medicinal cannabis in cancer populations, including the availability of assays to accurately assess cannabinoid levels, lack of clinical biomarkers and patient enrolment for pharmacokinetic studies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/162886